Anti-FliC Antibody Development

Creative Biolabs provides a full range of anti-Fagellin FliC antibody development services. Our high quality customized antibodies will contribute greatly to the success of your project, and the anti-FliC antibody can be conjugated with different bioactive agents to form a more promising therapeutic approach. Based on the advanced technology platform, professional scientists at Creative Biolabs offers antibody customization services for Salmonella and we are capable to supply anti-FliC antibody in either research quantities or on large scale for industrial applications.

Fagellin FliC

Flagellin is the primary component of bacterial flagella. The immunogenicity of bacterial flagellin has been reported in numerous studies. By its close interaction with the immune system, the flagellin represents an interesting adjuvant and vaccine candidate. Flagellin of Salmonella induces several pathways of immunity system, which leads to producing antibody and cytokines. As for our target, FliC could stimulate both cellular and humoral immune responses. The fliC and fljB genes encoding the two flagellar antigens present in Salmonella. Salmonella can undergo flagellar phase variation to alternately express these two different major flagellar antigens, phase 1 and phase 2, encoded by the fliC and fljB genes, respectively.

Fig.1 Model for the mechanism of genetic control of flagellar phase variation in Salmonella. (Yamamoto, 2006)

Structure of FliC

Flagella FliC is a virulence factor and protective antigen. The folded Salmonella flagellin protein assumes an “L” shaped structure, comprised of four unique domains, D0, D1, D2, D3. The 250 amino acids have been documented as mostly invariant among Gram-negative and Gram-positive bacteria. The unique protein epitopes present within Salmonella flagellins are characteristic and conserved for individual serovars and provide the basis in part for serotyping in the Kauffman-White scheme.

Fig.2 Flagellin domain organization presented on the structure of Salmonella enterica FliC. (Radomska, 2017)

Antibody of FliC

Studies have shown a high prevalence of Salmonella in various animals and humans. These strains usually possess high levels of drug-resistance. Monoclonal antibodies (mAbs) against flagellin have been shown to mediate protection in animal models against infections caused by Salmonella. The immunostimulatory properties of flagellin have further improved immune responses towards co-administered protein antigens after admixture, covalent linkage, or incorporation into non-covalent complexes. So, combining an approach designed to enhance the host immune response with antibiotic therapy against the drug-resistance pathogen is a promising therapy.

Features

• Comprehensive technical platform
• Fast turnaround time and competitive pricing
• Top professional team with rich experience in antibody development and modification

Creative Biolabs is capable to provide the largest and diversiform portfolio of mAbs products and services about different kinds of bacterial protein biomarker. The possibility of antibiotic cooperated with mAb could expand the therapeutic options, reduce the duration of therapy. Our proven and optimized platforms can help you quickly get satisfactory results for your Antibody-antibiotic Conjugate (AAC) projects. We also provide custom services to meet the clients’ specific demand. Please feel free to contact us for more details.

References

1. Yamamoto, S.; Kutsukake, K. (2006). FljA-mediated posttranscriptional control of phase 1 flagellin expression in flagellar phase variation of Salmonella enterica serovar Typhimurium. Journal of bacteriology, 188(3), 958-967.
2. Radomska, K. A.; et al. (2017). Importance of Campylobacter jejuni FliS and FliW in flagella biogenesis and flagellin secretion. Frontiers in microbiology, 8, 1060.

For Research Use Only. NOT FOR CLINICAL USE.